These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease? Geisler T; Gawaz M; Steinhubl SR; Bhatt DL; Storey RF; Flather M Pharmacol Ther; 2010 Aug; 127(2):95-107. PubMed ID: 20570595 [TBL] [Abstract][Full Text] [Related]
23. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Morimoto T; Fukui T; Lee TH; Matsui K Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702 [TBL] [Abstract][Full Text] [Related]
24. Current concepts in antiplatelet therapy for cardiovascular disease. Martinez A JAAPA; 2004 Mar; 17(3):16-20, 23-4; quiz 51-2. PubMed ID: 15314880 [No Abstract] [Full Text] [Related]
25. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Gurbel PA Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887 [TBL] [Abstract][Full Text] [Related]
26. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. Rodondi N; Bauer DC Am J Med; 2004 Oct; 117(7):528-30. PubMed ID: 15464713 [No Abstract] [Full Text] [Related]
27. Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies. Steinhubl SR Rev Cardiovasc Med; 2006; 7 Suppl 4():S12-9. PubMed ID: 17224886 [TBL] [Abstract][Full Text] [Related]
28. New input on antiplatelet treatment and registry studies. Agewall S Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):129-130. PubMed ID: 30052852 [No Abstract] [Full Text] [Related]
29. [Prescription and surveillance of antithrombotic agents. Part 2: antiplatelet agents]. Lecompte T Rev Prat; 2004 Apr; 54(7):791-4. PubMed ID: 15253299 [No Abstract] [Full Text] [Related]
30. Perioperative antiplatelet therapy: a knife-edged choice between thrombosis and bleeding still based on consensus rather than evidence. Peter K; Myles PS Thromb Haemost; 2011 May; 105(5):750-1. PubMed ID: 21384077 [No Abstract] [Full Text] [Related]
34. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. May AE; Geisler T; Gawaz M Thromb Haemost; 2008 Mar; 99(3):487-93. PubMed ID: 18327396 [TBL] [Abstract][Full Text] [Related]
38. Drug insight: aspirin resistance--fact or fashion? Patrono C; Rocca B Nat Clin Pract Cardiovasc Med; 2007 Jan; 4(1):42-50. PubMed ID: 17180149 [TBL] [Abstract][Full Text] [Related]
39. Critical GI issues for the cardiologist: new insights and understanding. Introduction. Faxon DP; Johnson DA Rev Cardiovasc Med; 2005; 6 Suppl 4():S1-2. PubMed ID: 17710071 [No Abstract] [Full Text] [Related]
40. Evidence-based prescribing and adherence to antiplatelet therapy--how much difference do they make to patients with atherothrombosis? Husted S Int J Cardiol; 2009 May; 134(2):150-9. PubMed ID: 19282042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]